Open Access

[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma

  • Authors:
    • Song Ye
    • Xin-Yi Zhao
    • Xiao-Ge Hu
    • Tang Li
    • Qiu-Ran Xu
    • Huan-Ming Yang
    • Dong-Sheng Huang
    • Liu Yang
  • View Affiliations

  • Published online on: September 19, 2022     https://doi.org/10.3892/or.2022.8411
  • Article Number: 196
  • Copyright : © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

November-2022
Volume 48 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye S, Zhao X, Hu X, Li T, Xu Q, Yang H, Huang D and Yang L: [Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 48: 196, 2022
APA
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H. ... Yang, L. (2022). [Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncology Reports, 48, 196. https://doi.org/10.3892/or.2022.8411
MLA
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H., Huang, D., Yang, L."[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma". Oncology Reports 48.5 (2022): 196.
Chicago
Ye, S., Zhao, X., Hu, X., Li, T., Xu, Q., Yang, H., Huang, D., Yang, L."[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma". Oncology Reports 48, no. 5 (2022): 196. https://doi.org/10.3892/or.2022.8411